For the bone mineral density secondary outcomes , total hip bone mineral density increased more in the teriparatide to denosumab group ( @ % -LSB- @ % CI @-@ -RSB- ) than in the denosumab to teriparatide group ( @ % -LSB- @-@ -RSB- , p = @ ) , but had the greatest increase in the combination to denosumab group ( @ % -LSB- @-@ -RSB- ; p = @ vs the teriparatide to denosumab group , p < @ vs the denosumab to teriparatide group ) .